Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic Amyloidosis due to Low-Grade Lymphoma.
Wechalekar AD, Chakraborty R, Lentzsch S. Wechalekar AD, et al. Among authors: lentzsch s. Hematol Oncol Clin North Am. 2020 Dec;34(6):1027-1039. doi: 10.1016/j.hoc.2020.08.016. Epub 2020 Oct 1. Hematol Oncol Clin North Am. 2020. PMID: 33099421 Review.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Chari A, et al. Among authors: lentzsch s. Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21. Blood. 2017. PMID: 28637662 Free PMC article. Clinical Trial.
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Spencer A, et al. Among authors: lentzsch s. Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20. Haematologica. 2018. PMID: 30237264 Free PMC article. Clinical Trial.
Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D, Leng S, Lentzsch S. Bhutani D, et al. Among authors: lentzsch s. Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):555-559. doi: 10.1016/j.clml.2019.03.029. Epub 2019 Apr 1. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31262668 Review.
Emerging drugs for the treatment of light chain amyloidosis.
Chakraborty R, Lentzsch S. Chakraborty R, et al. Among authors: lentzsch s. Expert Opin Emerg Drugs. 2020 Sep;25(3):299-317. doi: 10.1080/14728214.2020.1803829. Epub 2020 Aug 24. Expert Opin Emerg Drugs. 2020. PMID: 32731778 Review.
158 results